

Clinical Trial Protocol

Iranian Registry of Clinical Trials

31 May 2026

Assessment of the therapeutic effects of Anaheal plus supplement in patients with contact dermatitis

Protocol summary

Study aim

Investigating the therapeutic effect of Anahil Plus supplement in patients with contact dermatitis

Design

clinical trial with control groups, community-based and pragmatic, with a parallel group, single-blind, randomized, on 50 patients

Settings and conduct

This study was performed on patients over 12 years old with contact dermatitis who referred to the Tehran Islamic Azad University Hospitals, and the first group will receive Anahil Plus, which contains bromelain and curcumin, and the second group will receive a placebo that contains lactose. The number of patients is 50, which was announced by a statistician based on the number of patients with contact dermatitis who visited the office in the last year and in a period of three months. Each of the experimental and control groups includes 25 people. Patients will participate in the study according to the doctor's diagnosis of having contact dermatitis and according to demographic information and personal consent and will be placed in one of the control or experimental groups. The informed consent form that has been prepared in advance will be provided to the patients so that they are fully familiar with the study process.

Participants/Inclusion and exclusion criteria

Adult patients (over 12 years old) with contact dermatitis; Allergy to pineapple, celery, carrot and fennel, having hemophilia, taking two anti-platelet drugs or one anti-platelet drug and an anticoagulant, severe kidney failure (GFR<30), severe liver failure (Child pugh B, C), Pregnant, lactating women

Intervention groups

Adult patients with contact dermatitis who will receive Anahil Plus supplement in addition to standard treatment (moisturizer). In control group in addition to the standard treatment, they will receive a placebo that contains lactose.

Main outcome variables

The surface of the affected area, redness, inflammation, itching

General information

Reason for update

The code of ethics and sponsor was entered incorrectly

Acronym

IRCT registration information

IRCT registration number: **IRCT20150706023084N16**

Registration date: **2023-08-21, 1402/05/30**

Registration timing: **prospective**

Last update: **2023-11-06, 1402/08/15**

Update count: **1**

Registration date

2023-08-21, 1402/05/30

Registrant information

Name

MARYAM SHIEHMORTEZA

Name of organization / entity

AZAD UNIVERSITY PHARMACEUTICAL SCIENCES

Country

Iran (Islamic Republic of)

Phone

+98 212640056

Email address

shiehmorteza@iaups.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-08-23, 1402/06/01

Expected recruitment end date

2023-11-22, 1402/09/01

Actual recruitment start date

empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Assessment of the therapeutic effects of Anaheal plus supplement in patients with contact dermatitis

Public title
Anaheal plus supplement in contact dermatitis

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Adult patients (over 12 years old) Patient with contact dermatitis
Exclusion criteria:
Allergy to pineapple, celery, carrot and fennel having hemophilia taking two anti-platelet drugs or one anti-platelet drug and an anticoagulant severe kidney failure (GFR<30) severe liver failure (Child pugh B, C)
Pregnancy lactation

Age
From **12 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Care provider
- Data analyser

Sample size
Target sample size: **50**

Randomization (investigator's opinion)
Randomized

Randomization description
After the diagnosis of the disease by the dermatologist, using the rand number site, each patient was assigned a number.

Blinding (investigator's opinion)
Single blinded

Blinding description
This study is conducted in single blind way, so that the patients are not aware of the contents of the received packages that contain Bremelin and Curcumin or placebo. Conventionally, the packages containing supplement number one and the packages containing placebo number two. We attribute Using rand number, we determine whether to give medicine or placebo to each patient.

Placebo
Used

Assignment
Parallel

Other design features
For all patients (both test group and control group), we prescribe the standard treatment that is moisturizing. In addition to the standard treatment, the test group also

receives Anahil Plus supplement twice a day. The control group will receive a placebo instead of a supplement. After a month, we will re-examine the factors of the involvement level, redness, inflammation and itching.

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Department of Pharmaceutical Sciences, Tehran Islamic Azad University of Medical

Street address

Dr Shariati Ave., Gholhak, Yakhchal Ave., Islamic Azad University of Pharmaceutical Sciences Branch

City

Tehran

Province

Tehran

Postal code

193956466

Approval date

2023-05-24, 1402/03/03

Ethics committee reference number

IR.IAU.PS.REC.1402.101

Health conditions studied

1

Description of health condition studied

Irritant contact dermatitis

ICD-10 code

L24.9

ICD-10 code description

Irritant contact dermatitis, unspecified cause

Primary outcomes

1

Description

The surface of the affected area

Timepoint

30 days

Method of measurement

Measuring with a ruler

2

Description

Redness

Timepoint

30 days

Method of measurement

According to REEDA

3

Description

Edema

Timepoint

30 days

Method of measurement

According to REEDA

4

Description

itching

Timepoint

30 days

Method of measurement

Ask the patient

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: including 25 patients who are diagnosed with contact dermatitis by a dermatologist and consume Anahil Plus supplement produced by the company (two tablets daily) plus moisturizer as a standard treatment for 30 days. The questionnaire form is filled at the beginning and after one month.

Category

Treatment - Drugs

2

Description

Control group: includes 25 patients who are diagnosed with contact dermatitis by a dermatologist and use standard moisturizer as a treatment for 30 days along with a placebo containing lactose. The relevant questionnaire is filled at the beginning and 30 days later.

Category

Placebo

Recruitment centers

1

Recruitment center**Name of recruitment center**

Booali hospital

Full name of responsible person

Hanieh Jalalian Targhi

Street address

Damavand Street, not reaching Imam Hossein Square, Bu Ali Hospital

City

Tehran

Province

Tehran

Postal code

1711734365

Phone

+98 21 3334 8036

Email

Booali.hospital96@gmail.com

Sponsors / Funding sources

1

Sponsor**Name of organization / entity**

Parmoon Salamat Amin Pharmaceutical Company

Full name of responsible person

Mohammad Reza Anbiaei

Street address

West Nafisi Alley, Baradaran Sarafha St, Saadat Abad Ave

City

Tehran

Province

Tehran

Postal code

1998863174

Phone

+98 21 8869 1099

Email

Info@spameda.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Parmoon Salamat Amin Pharmaceutical Company

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Industry

Person responsible for general inquiries

Contact**Name of organization / entity**

Islamic Azad University

Full name of responsible person

Maryam Shiehmorteza

Position

Assistant professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

No.99, Yakhckal street, DR Shariati Avenue

City

Tehran

Province

Tehran

Postal code

1916893813

Phone

+98 21 2264 0056

Fax

Email

Shiehmorteza@iaups.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Islamic Azad University

Full name of responsible person

Maryam Shiehmorteza

Position

Associated professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

No.99, Yakhchal street, Dr Shariati Avenue

City

Tehran

Province

Tehran

Postal code

1916893813

Phone

+98 21 2264 0056

Email

Shiehmorteza@iaups.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Islamic Azad University

Full name of responsible person

Hanieh Jalalian Targhi

Position

Pharmacy student

Latest degree

A Level or less

Other areas of specialty/work

Medical Pharmacy

Street address

No.99, Yakhchal street, Dr. Shariati avenue

City

Tehran

Province

Tehran

Postal code

1916893813

Phone

+98 21 2264 0056

Email

Hjalaliant@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Data are collected in the form of a questionnaire

When the data will become available and for how long

After the intervention

To whom data/document is available

Qualified persons

Under which criteria data/document could be used

Used for scientific advancement in the field under study

From where data/document is obtainable

Clinical office of Islamic Azad University, Medical science of tehran, Faculty of pharmacy

What processes are involved for a request to access data/document

Request in writing by going through legal procedures.

Comments